Consistency Among CDRH Review Divisions Improves, But Industry Wants More
This article was originally published in The Gray Sheet
Executive Summary
A new report from the California Healthcare Institute shows a positive convergence of performance among FDA’s device review divisions, but the biomedical industry group thinks more policy reforms that build on models from the best performing CDRH divisions and branches might be warranted.
You may also be interested in...
PMA Approvals On Track For 15-Year High
The agency has so far approved a total of 36 original PMAs and panel-track supplements in 2015, the highest total at this point in the year since 2001.
Calls For More FDA Training In Lead Up To User-Fee Negotiations
Device firms will be pushing for more reviewer consistency and to avoid a major increase in fees during upcoming negotiations with FDA to reauthorize the Medical Device User Fee Act. The MDUFA IV reauthorization process starts as Congress is already considering major regulatory reforms and will finish under a new administration in the White House.
Device Reg Issues In Play As FDA Kicks Off User Fee Renewal Effort
FDA will host a public meeting July 13 to hear public input in advance of agency-industry negotiations to reauthorize the device user-fee program. Industry appears to feel better about the device-review program than it did during the prior user-fee program, but what the top issues will be during negotiations this time around remain to be seen. Ongoing reform efforts in Congress will impact the process.